MODERNA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 147 USD | -2.66% |
|
+0.07% | +48.75% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
151
USD
Average target price
143.9
USD
Spread / Average Target
-4.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +48.75% | 57.87B | |
| +41.65% | 40.25B | |
| -7.34% | 39.94B | |
| -5.96% | 28.54B | |
| +12.43% | 26.4B | |
| -20.12% | 19.33B | |
| +30.27% | 12.4B | |
| -0.69% | 12.23B | |
| +24.79% | 12.2B | |
| -10.36% | 11.06B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
